Clicky

Ocuphire Pharma, Inc.(OCUP)

Description: Ocuphire is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances, pharmacologically-induced mydriasis, and presbyopia. Ocuphire’s second product candidate, APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late stage development, regulatory preparation, and commercialization of drugs in key global markets.


Keywords: Diabetes Organ Systems Inflammation Ophthalmology Eye Vision Ophthalmic Vascular Disease Diabetic Retinopathy Retina Blindness Diabetic Macular Edema Macular Edema Retinopathy Presbyopia Night Vision Angiogenesis Molecule Product

Home Page: www.ocuphire.com

OCUP Technical Analysis

37000 Grand River Avenue
Farmington Hills, MI 48335
United States
Phone: 248 681 9815


Officers

Name Title
Ms. Mina Patel Sooch M.B.A., MBA Founder, CEO, Pres, Treasurer & Vice Chair of the Board
Ms. Amy Zaremba Rabourn C.P.A., CPA, MAcc VP of Fin. & Principal Accounting Officer
Mr. Bernhard Hoffmann M.B.A. VP of Corp. Devel. & Operations and Sec.
Dr. Daniela C. Oniciu Ph.D. Global Head of R&D, Chemistry and Product Devel.
Dr. Mitchell Brigell Ph.D. Head of Clinical Devel. & Strategy
Mr. Chris Ernst Global Head of QA & Manufacturing
Ms. Bindu Manne Head of Market Devel. & Commercialization
Mr. Erik Sims Director & Corp. Controller

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 5.3958
Price-to-Sales TTM: 92.1672
IPO Date: 2005-05-23
Fiscal Year End: December
Full Time Employees: 8
Back to stocks